poisar

Stocks · News reference

OPKO Health Issues Additional $125M Of Senior Secured Notes To KKR's HealthCare Royalty For Non-Dilutive Funding

Benzinga Newsdesk

The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

OPK
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?

    STERIS reported strong Q1 fiscal 2027 results with adjusted EPS of $2.59 (up 10.7% YoY) beating estimates by 1.97%, driven by higher volume, pricing, and productivity across all segments. However, revenues of $1.49 billion missed consensus by 0.83%. The company reaffirmed its fiscal 2027 guidance for 7-8% revenue growth and $11.10-$11.30 adjusted EPS. Despite solid earnings, shares have underperformed the S&P 500 by 2.1% since the report.

    STEOPK
  2. Na

    Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?

    Waters Corporation reported Q2 2026 adjusted earnings of $3.05 per share, beating consensus estimates by 1.33%, with revenues of $1.645 billion surging 113.4% year-over-year. The company raised its 2026 organic constant-currency revenue growth guidance to 7%-9% and lifted adjusted earnings guidance to $14.45-$14.65 per share, driven by strong performance across its Analytical Sciences and newly acquired Biosciences and Diagnostic Solutions divisions. Shares have outperformed the S&P 500 by 3.1% over the past month.

    WATOPK
  3. SEC EDGAR

    8-K filing — OPKO HEALTH, INC. (OPK)

    Filed: 2026-08-14 AccNo: 0001193125-26-352370 Size: 161 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

    OPK